(Q45915556)

17 December 2017

title

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. (English)

1 reference

17 December 2017

chronic obstructive pulmonary disease

main subject

patient

0 references

0 references

budesonide/formoterol

1 reference

2

1 reference

17 December 2017

Tobias Welte

1

object named as

Tobias Welte

1 reference

17 December 2017

Paul Hernandez

3

1 reference

17 December 2017

Göran Eriksson

4

1 reference

17 December 2017

Stefan Peterson

5

1 reference

17 December 2017

Tomasz Polanowski

6

1 reference

17 December 2017

Romain Kessler

7

1 reference

17 December 2017

language of work or name

English

0 references

publication date

30 July 2009

1 reference

17 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

17 December 2017

volume

180

1 reference

17 December 2017

page(s)

741-750

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

How corticosteroids control inflammation: Quintiles Prize Lecture 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

Methodological issues in therapeutic trials of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200904-0492OC

10.1164/RCCM.200904-0492OC

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

19644045

1 reference

17 December 2017